(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 June 2020 (04.06.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/109526 A8

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/14* (2017.01)
A61K 9/08 (2006.01) *A61P 3/10* (2006.01)
A61K 38/22 (2006.01)

(21) International Application Number:
PCT/EP2019/083022

(22) International Filing Date:
29 November 2019 (29.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/773,651 30 November 2018 (30.11.2018) US
62/821,382 20 March 2019 (20.03.2019) US

(71) Applicant: **EIRGEN PHARMA LTD.** [IE/IE]; Westside Business Park, Old Kilmeaden Road, Waterford, X91 YV67 (IE).

(72) Inventors: **CONNOP, Bruce Peter**; 116 Glencairn Ave, Toronto, Ontario M4R 1M9 (CA). **SPENCER, Dorothy Melissa Lynn**; 153 Forman Ave, Toronto, Ontario M4S 2R9 (CA). **SINGH, Jagatraj**; 64 Grover Drive, Scarborough, Ontario M1C 4V7 (CA). **KERKOW, Donald Edmund**; 2201 Gilman Street, Durham, North Carolina 27703 (US). **BUCZEK, Pawel Dominik**; 320 Sunset Creek Circle, Chapel Hill, North Carolina 27516 (US). **HALBLEIB, Cale Michael**; 208 Kings Drive, Apex, North Carolina 27502 (US).

(74) Agent: **PEARL COHEN ZEDEK LATZER BARATZ UK LLP**; The Gridiron Building, One Pancras Square, London Greater London N1C 4AG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *with information concerning incorporation by reference of missing element or part (Rule 20.6)*

(88) Date of publication of the international search report:
17 September 2020 (17.09.2020)

(48) Date of publication of this corrected version:
07 October 2021 (07.10.2021)

(15) Information about Correction:
see Notice of 07 October 2021 (07.10.2021)

(54) Title: OXYNTOMODULIN PEPTIDE ANALOG FORMULATIONS

(57) Abstract: The present invention relates to GLP-1 and/or glucagon receptor agonists (for example, oxyntomodulin peptide analogs), pharmaceutically acceptable salts thereof, formulations comprising the same, and uses thereof for treating diabetes and/or obesity or associated diseases or disorders.

WO 2020/109526 A8